This study is in progress, not accepting new patients

A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US

a study on Cardiomyopathy

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
study ends around

Description

Summary

The purpose of this study is to evaluate the real-world safety and effectiveness of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) initiated on mavacamten at certain high volume HCM centers in the US

Official Title

MavAcamten Real World eVidEnce coLlaboration in HCM (MARVEL-HCM)

Keywords

Obstructive Hypertrophic Cardiomyopathy (oHCM), Cardiomyopathies, Hypertrophic Cardiomyopathy, Hypertrophy, Mavacamten

Eligibility

You can join if…

Open to people ages 18 years and up

  • Age ≥ 18 years at the index date
  • Prescription of mavacamten for the treatment of Obstructive hypertrophic cardiomyopathy (oHCM) with NYHA Class II or III
  • ≥ 12 weeks of follow-up after prescription of mavacamten, except for the baseline data reporting

You CAN'T join if...

  • Data collection as part of a clinical trial during the study period
  • Participation in a myosin inhibitor clinical trial

Location

  • UCSF (UCSF)
    San Francisco California 94118 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bristol-Myers Squibb
Links
BMS Clinical Trial Information FDA Safety Alerts and Recalls
ID
NCT07107373
Study Type
Observational
Participants
Expecting 150 study participants
Last Updated